


Scientists at UCSF-PHI Center of Excellence map the genetic progression of invasive skin cancer

Utilizing precision genetic engineering and PHI's HoloMonitor technology, scientists at University of California, San Francisco, have for the first time been able to monitor and map how mutations break down the genetic protection against skin cancer, allowing harmless moles to transform into invasive skin cancer. The new research, which promises to improve skin cancer treatment by allowing malignant forms to be identified earlier, was recently published in two companion papers in the prestigious and high impact scientific journal Cancer Cell.



"It is our role and vision to provide medical scientists with the new scientific tools they need to achieve significant advancements. The discoveries made by the scientists at UCSF are a perfect example of this", said Peter Egelberg, CEO and founder of PHI.

REFERENCES

- [Evolution of Melanoma Reveals Opportunities for Intervention](#), UCSF News Center
- [Bi-allelic Loss of CDKN2A Initiates Melanoma Invasion via BRN2 Activation](#), Cancer Cell
- [Genomic and Transcriptomic Analysis Reveals Incremental Disruption of Key Signaling Pathways during Melanoma Evolution](#), Cancer Cell

ABOUT PHI

Phase Holographic Imaging (PHI) leads the ground-breaking development of time-lapse cytometry instrumentation and software. With the first instrument introduced in 2011, the company today offers a range of products for long-term quantitative analysis of living cell dynamics that circumvent the drawbacks of traditional methods requiring toxic stains. Head-quartered in Lund, Sweden, PHI trades through a network of international distributors. Committed to promoting the science and practice of time-lapse cytometry, PHI is actively expanding its customer base and scientific collaborations in cancer research, inflammatory and autoimmune diseases, stem cell biology, gene therapy, regenerative medicine and toxicological studies.

For additional information, please contact:

Peter Egelberg, CEO

Tel: +46 703 19 42 74

E-mail: ir@phiab.se

Web: www.phiab.se